Ancora Heart Inc, based in Santa Clara, CA, is dedicated to addressing the challenges faced by individuals battling heart failure, a leading cause of mortality in modern times. The company focuses on the development of AccuCinch®, an innovative therapy designed to expand treatment options for patients grappling with heart failure, also known as congestive heart failure (CHF).
The AccuCinch Ventricular Restoration System, designated as a Breakthrough Device by the FDA, aims to enhance the quality of life for individuals experiencing common heart failure symptoms such as fatigue, breathing difficulties, and memory issues. By leveraging early feasibility clinical data, Ancora Heart aims to showcase the positive impact of the AccuCinch System on patients' quality of life, functional capacity, and potential for reverse remodeling, specifically for those with heart failure and reduced ejection fraction (HFrEF).
By enrolling patients in the CORCINCH-HF Study, a randomized, controlled clinical trial, Ancora Heart is actively pursuing further evidence of the AccuCinch System's benefits for heart failure patients. Committed to innovation and teamwork, Ancora Heart strives to build upon decades of expertise to provide relief and comfort for individuals struggling with heart failure.
Generated from the website content
